WHO Granted Prequalification to EuBiologics Typhoid Vaccine
The World Health Organization approved the EuTYPH-C vaccine for use, opening the path for global distribution.
Updated on Sept. 27, 2026 in Diseases — General
Live Poll
Should international health agencies prioritize lower-cost vaccine suppliers to improve global health equity?
In August 2026, the World Health Organization granted prequalification to EuTYPH-C, a typhoid conjugate vaccine developed by EuBiologics. This approval allows the vaccine to enter international procurement channels to help combat a disease that caused an estimated 6.2 million cases and 72,000 deaths worldwide in 2023.
Why it matters
International procurement agencies prioritize these approvals to diversify supply chains and lower costs for vaccines, which provide vital immunity to children as young as 6 months. The addition of a new supplier marks a significant shift from the current dependence on three primary manufacturers based in India.
The EuTYPH-C vaccine underwent clinical trials funded by 4 billion won in milestone-based tranches, with EuBiologics contributing 50 percent of the costs. EuBiologics expects a UNICEF allocation of 4 million to 5 million doses in the second half of 2027.
The players
World Health Organization
This specialized agency of the United Nations is responsible for international public health and the oversight of global vaccine standards.
EuBiologics
This South Korean biotechnology company specializes in the development and manufacturing of vaccines and biopharmaceutical products.
RIGHT Foundation
This organization funds global health research and development projects to address infectious diseases in developing countries.
UNICEF
This agency of the United Nations provides humanitarian and developmental aid to children worldwide, including large-scale vaccine procurement.
The details
The vaccine's development was supported by the RIGHT Foundation, which financed phase 3 clinical trials conducted across Kenya and Senegal. Following this regulatory milestone, EuBiologics plans to obtain a Korean export license in October 2026 and file for further WHO variation recognition in November 2026.
Timeline
The RIGHT Foundation was established in 2018.
Global typhoid statistics were recorded for 2023.
The WHO granted prequalification to EuTYPH-C in August 2026.
A target UNICEF vaccine allocation is set for the second half of 2027.
Health Landscape
This development breaks the historical reliance on three India-based manufacturers that previously held the majority of WHO prequalified typhoid vaccine supply. By introducing a new supplier, the market moves toward greater stability and reduced costs for international procurement agencies.
Increased global vaccine supply will provide wider access to typhoid protection for children as young as 6 months. This expanded availability helps reduce the overall health burden in high-risk regions by ensuring more consistent access to preventative care.
The takeaway
The addition of a new prequalified vaccine supplier enhances global health security by mitigating risks associated with supply chain bottlenecks. Policymakers and health agencies will look to this model as a blueprint for diversifying access to essential medicines in underserved regions.
What happens next
EuBiologics plans to receive a Korean export license for the single-dose vial version of the vaccine in October 2026 and intends to file for WHO variation recognition in November 2026.
Further reading
Learn more about ongoing immunization efforts on the Diseases — General page.
Source note: This article includes information reported by The Korea Herald.
Live Poll
Should international health agencies prioritize lower-cost vaccine suppliers to improve global health equity?
